There are currently 113 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
BXCL501 for Agitation in Schizophrenia
NCT03708315
Recruiting
Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness, threatening gestures, and, in some cases, aggressive or violent behavior. While agitation may have various underlying causes, patients with schizophrenia are especially vulnerable to acute episodes of agitation, especially during exacerbation of disease, and clinicians do not always diagnose these episodes early enough. Agitation associated with psychosis is a frequent reason for emergency departme... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
PET Scanning in Parkinson s Disease
NCT00024622
Recruiting
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Parkinson's Disease
Register for Updates
Young Adults With Violent Behavior During Early Psychosis
NCT05756855
Recruiting
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
Gender:
All
Ages:
Between 16 years and 30 years
Trial Updated:
06/04/2024
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder, Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
Register for Updates
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227703
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2024
Locations: Bentonville, Arkansas, Bentonville, Arkansas +26 locations
Conditions: Schizophrenia
Register for Updates
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2024
Locations: Little Rock, Arkansas, Little Rock, Arkansas +27 locations
Conditions: Schizophrenia
Register for Updates
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
NCT05299749
Recruiting
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/17/2024
Locations: Boston VA Healthcare System, Brockton, Brockton, Massachusetts
Conditions: Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Register for Updates
Effects of Brain Stimulation on Higher-Order Cognition
NCT03814967
Recruiting
The purpose of this study is to better understand the neural correlates of higher-order cognition, both in the healthy brain and in schizophrenia, and to determine how these mechanisms are modulated by transcranial direct current stimulation (tDCS) at frontal and occipital scalp sites. Testing the effects of tDCS at these scalp sites on cognitive task performance will help us understand the roles of the brain regions corresponding to these sites during higher-order cognitive processing (language... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
05/15/2024
Locations: Imaging Research Center, Sacramento, California
Conditions: Schizophrenia
Register for Updates
Prebiotic Treatment in People With Schizophrenia
NCT05527210
Recruiting
The proposed project is based on the observation that schizophrenia is characterized by a chronic pro-inflammatory state, which contributes to the severity of a number of the clinical manifestations of the illness, including cognitive impairments, the treatment of which represents a critically important unmet therapeutic need.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/15/2024
Locations: Maryland Psyciatric Research Center, Catonsville, Maryland
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: Phoenix, Arizona, Phoenix, Arizona +86 locations
Conditions: Schizophrenia
Register for Updates
Mobile Self-Tracking
NCT05023252
Recruiting
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness, suicide, incarceration, and hospitalization. Treatment visits can be infrequent. Illness exacerbations usually occur with no clinician awareness, leaving little opportunity to make treatment adjustments. Tools are needed that quickly detect illness worsening. At least tw... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California
Conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
Register for Updates
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
NCT05838625
Recruiting
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Click Therapeutics, New York, New York
Conditions: Schizophrenia
Register for Updates
Horyzons: Implementation and Integration in Clinical Practice
NCT06002958
Recruiting
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP) clinics in North Carolina. Providers (clinicians and peers support specialists) will be recruited from FEP clinics to assess Horyzons implementation and integration within clinical care at three time points (baseline, 6 months, and 12 months). Further, individuals exper... Read More
Gender:
All
Ages:
Between 16 years and 35 years
Trial Updated:
05/08/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Register for Updates